AveXis, Inc. (NASDAQ:AVXS) fell NaN on Tuesday . The stock traded as low as $88.42 and last traded at $0.00. 508,500 shares were traded during mid-day trading, an increase of Infinity from the average session volume of 0 shares.

Several research firms have recently weighed in on AVXS. Jefferies Group LLC reissued a “buy” rating and issued a $108.00 price objective (up from $92.00) on shares of AveXis in a research report on Friday, August 11th. BMO Capital Markets reissued a “buy” rating and issued a $123.00 price objective on shares of AveXis in a research report on Friday, August 11th. Morgan Stanley reissued an “overweight” rating and issued a $118.00 price objective on shares of AveXis in a research report on Wednesday, August 9th. Chardan Capital set a $103.00 price objective on AveXis and gave the company a “buy” rating in a research report on Sunday, June 18th. Finally, Evercore ISI initiated coverage on AveXis in a research note on Wednesday, August 16th. They issued an “outperform” rating and a $120.00 target price for the company. Two research analysts have rated the stock with a sell rating, three have issued a hold rating and thirteen have given a buy rating to the company. The company has a consensus rating of “Buy” and a consensus price target of $99.29.

The company’s 50-day moving average price is $93.16 and its 200 day moving average price is $80.70. The stock’s market capitalization is $2.88 billion.

AveXis (NASDAQ:AVXS) last released its quarterly earnings results on Thursday, August 10th. The company reported ($2.07) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.97) by ($1.10). During the same quarter last year, the company posted ($0.68) earnings per share. Equities research analysts predict that AveXis, Inc. will post ($6.04) EPS for the current fiscal year.

In other AveXis news, VP Sukumar Nagendran sold 1,780 shares of the stock in a transaction that occurred on Monday, July 3rd. The stock was sold at an average price of $81.88, for a total value of $145,746.40. Following the transaction, the vice president now owns 1,780 shares in the company, valued at $145,746.40. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. In the last quarter, insiders sold 5,340 shares of company stock worth $474,637. Corporate insiders own 18.60% of the company’s stock.

Large investors have recently made changes to their positions in the business. Russell Investments Group Ltd. boosted its holdings in AveXis by 41.7% in the second quarter. Russell Investments Group Ltd. now owns 24,871 shares of the company’s stock worth $2,043,000 after acquiring an additional 7,321 shares in the last quarter. Tocqueville Asset Management L.P. bought a new position in AveXis in the second quarter worth approximately $552,000. TimesSquare Capital Management LLC bought a new position in AveXis in the second quarter worth approximately $6,162,000. Credit Suisse AG boosted its holdings in AveXis by 36.4% in the first quarter. Credit Suisse AG now owns 63,228 shares of the company’s stock worth $4,807,000 after acquiring an additional 16,876 shares in the last quarter. Finally, Swiss National Bank boosted its holdings in AveXis by 3.0% in the first quarter. Swiss National Bank now owns 27,400 shares of the company’s stock worth $2,083,000 after acquiring an additional 800 shares in the last quarter. Institutional investors and hedge funds own 94.71% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: “AveXis, Inc. (AVXS) Trading Down NaN” was posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this article on another website, it was illegally copied and republished in violation of international trademark and copyright laws. The original version of this article can be read at https://www.thecerbatgem.com/2017/09/28/avexis-inc-avxs-trading-down-nan.html.

About AveXis

AveXis, Inc is a clinical-stage gene therapy company. The Company operates through the developing and commercializing gene therapy treatments for patients suffering from neurological genetic diseases segment. The Company’s product candidate, AVXS-101, is its gene therapy product candidate that is in a Phase I clinical trial for the treatment of spinal muscular atrophy (SMA) Type 1, which is a genetic disorder characterized by motor neuron loss and associated muscle deterioration.

Receive News & Stock Ratings for AveXis Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AveXis Inc. and related stocks with our FREE daily email newsletter.